title: Joint National Committee VI: individualized versus indiscriminate therapy for hypertension.
abstract: The treatment of hypertension has progressed from a few nontoxic choices to the close to 60 individual drugs listed in the recommendations of the Sixth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Many combination drugs are also listed for use. The JNC documents have suggested initial therapy with diuretic or beta-blocker since 1993. Practitioners have followed these suggestions or not followed them on the basis of their personal bias. Since the 1997 JNC VI report, several studies that seem to support an individualistic approach to treatment have been reported. This is an exciting time in hypertension research. Clinicians who treat this common disorder will continue to line up as indiscriminate or individualistic prescribers, depending on their interpretation of the available data. We expect the hypertensive patient to be the winner of this increased attention.
authors.affiliation: Medical Care Affiliates, 780 Boylston Street, Plaza One, Boston, MA 02199, USA. ctifft@ix.netcom.com
authors.forename: C P
authors.initials: CP
authors.lastname: Tifft
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000809:Angiotensins / Q000037:antagonists & inhibitors; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001291:Attitude of Health Personnel; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D010820:Physicians; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011480:Protease Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D004338:Drug Combinations; D011480:Protease Inhibitors; D049993:Sodium Chloride Symporter Inhibitors